216 related articles for article (PubMed ID: 12481191)
1. BMS-204352: a potassium channel opener developed for the treatment of stroke.
Jensen BS
CNS Drug Rev; 2002; 8(4):353-60. PubMed ID: 12481191
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels.
Gribkoff VK; Starrett JE; Dworetzky SI; Hewawasam P; Boissard CG; Cook DA; Frantz SW; Heman K; Hibbard JR; Huston K; Johnson G; Krishnan BS; Kinney GG; Lombardo LA; Meanwell NA; Molinoff PB; Myers RA; Moon SL; Ortiz A; Pajor L; Pieschl RL; Post-Munson DJ; Signor LJ; Srinivas N; Taber MT; Thalody G; Trojnacki JT; Wiener H; Yeleswaram K; Yeola SW
Nat Med; 2001 Apr; 7(4):471-7. PubMed ID: 11283675
[TBL] [Abstract][Full Text] [Related]
3. BMS-204352 (Bristol Myers Squibb).
Mackay KB
Curr Opin Investig Drugs; 2001 Jun; 2(6):820-3. PubMed ID: 11572663
[TBL] [Abstract][Full Text] [Related]
4. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury.
Cheney JA; Weisser JD; Bareyre FM; Laurer HL; Saatman KE; Raghupathi R; Gribkoff V; Starrett JE; McIntosh TK
J Cereb Blood Flow Metab; 2001 Apr; 21(4):396-403. PubMed ID: 11323525
[TBL] [Abstract][Full Text] [Related]
5. The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.
Mayanagi K; Gáspár T; Katakam PV; Kis B; Busija DW
J Cereb Blood Flow Metab; 2007 Feb; 27(2):348-55. PubMed ID: 16736040
[TBL] [Abstract][Full Text] [Related]
6. Voltage-independent KCNQ4 currents induced by (+/-)BMS-204352.
Schrøder RL; Strøbaek D; Olesen SP; Christophersen P
Pflugers Arch; 2003 Aug; 446(5):607-16. PubMed ID: 12851819
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties.
Hewawasam P; Erway M; Moon SL; Knipe J; Weiner H; Boissard CG; Post-Munson DJ; Gao Q; Huang S; Gribkoff VK; Meanwell NA
J Med Chem; 2002 Mar; 45(7):1487-99. PubMed ID: 11906290
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke.
Campbell CA; Barone FC; Benham CD; Hadingham SJ; Harries MH; Harling JD; Hills JM; Lewis VA; Mackay KB; Orlek BS; White RF; Parsons AA; Hunter AJ
Eur J Pharmacol; 2000 Aug; 401(3):419-28. PubMed ID: 10936502
[TBL] [Abstract][Full Text] [Related]
9. KCNQ4 channel activation by BMS-204352 and retigabine.
Schrøder RL; Jespersen T; Christophersen P; Strøbaek D; Jensen BS; Olesen SP
Neuropharmacology; 2001 Jun; 40(7):888-98. PubMed ID: 11378159
[TBL] [Abstract][Full Text] [Related]
10. Disposition of radiolabeled BMS-204352 in rats and dogs.
Krishna R; Yao M; Srinivas NR; Shah V; Pursley JM; Arnold M; Vachharajani NN
Biopharm Drug Dispos; 2002 Jan; 23(1):41-6. PubMed ID: 11891672
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of Ca2+-activated K+ channel activator, BMS on L-type Ca2+ channels in rat ventricular myocytes.
Son YK; Choi SW; Jung WK; Jo SH; Jung ID; Park YM; Choi IW; Sin JI; Shim EB; Kim N; Han J; Park WS
Life Sci; 2011 Aug; 89(9-10):331-6. PubMed ID: 21763323
[TBL] [Abstract][Full Text] [Related]
12. Voltage-gated cation channel modulators for the treatment of stroke.
Gribkoff VK; Winquist RJ
Expert Opin Investig Drugs; 2005 May; 14(5):579-92. PubMed ID: 15926865
[TBL] [Abstract][Full Text] [Related]
13. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.
Dupuis DS; Schrøder RL; Jespersen T; Christensen JK; Christophersen P; Jensen BS; Olesen SP
Eur J Pharmacol; 2002 Feb; 437(3):129-37. PubMed ID: 11890900
[TBL] [Abstract][Full Text] [Related]
14. Potassium channel blockers and openers as CNS neurologic therapeutic agents.
Judge SI; Smith PJ; Stewart PE; Bever CT
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):200-28. PubMed ID: 18221232
[TBL] [Abstract][Full Text] [Related]
15. Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception.
Sivarao DV; Newberry K; Langdon S; Lee AV; Hewawasam P; Plym MJ; Signor L; Myers R; Lodge NJ
J Pharmacol Exp Ther; 2005 May; 313(2):840-7. PubMed ID: 15701710
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
17. Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener.
Kiesewetter DO; Jagoda EM; Starrett JE; Gribkoff VK; Hewawasam P; Srinivas N; Salazar D; Eckelman WC
Nucl Med Biol; 2002 Jan; 29(1):55-9. PubMed ID: 11786276
[TBL] [Abstract][Full Text] [Related]
18. Investigation of AM-36: a novel neuroprotective agent.
Callaway JK
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):913-8. PubMed ID: 11703395
[TBL] [Abstract][Full Text] [Related]
19. Voltage-gated potassium channels activated during action potentials in layer V neocortical pyramidal neurons.
Kang J; Huguenard JR; Prince DA
J Neurophysiol; 2000 Jan; 83(1):70-80. PubMed ID: 10634854
[TBL] [Abstract][Full Text] [Related]
20. In vivo characterization of the mitochondrial selective K(ATP) opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects.
Grover GJ; D'Alonzo AJ; Darbenzio RB; Parham CS; Hess TA; Bathala MS
J Pharmacol Exp Ther; 2002 Oct; 303(1):132-40. PubMed ID: 12235243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
